US › Healthcare

CytoMed Therapeutics Limited Ordinary Shares (GDTC)

US · Healthcare · Biotechnology

$0.890.00%

Last close · 2026-09-17

Latest quarter · ended 2025-12-31

Revenue

$167,945

Revenue YoY

+18.5%

Net profit

$-1.7M

EPS

$0.00

EPS estimate

$-0.04

Net margin

-1,030.7%

EPS came in at 0.00 against a street estimate of -0.04 — a beat of 100.0%.

Key statistics

Market cap

$9.6M

Forward P/E

0.0

P/B

1.82

Book value

$0.44

EPS (TTM)

$-0.27

52-week high

$3.68

52-week low

$0.68

50-day MA

$0.93

200-day MA

$1.10

Beta

0.05

Analyst view

Analysts rate CytoMed Therapeutics Limited Ordinary Shares a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.00.

Shareholding

Insiders

70.47%

Institutions

0.14%

Largest institutional holders

Fund	Stake
XTX Topco Ltd	0.09%
Axiom Investment Management LLC	0.06%
UBS Group AG	0.05%
Advisor Group Holdings, Inc.	0.00%
StoneX Group Inc	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CytoMed Therapeutics Limited Ordinary Shares — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.